Cannabinoid CB1 receptors are early DownRegulated followed by a further UpRegulation in the basal Ganglia of mice with deletion of specific park genes

Journal of Neural Transmission, Supplementa

Volumn , Issue 73, 2009, Pages 269-275

  García Arencibia, Moisés ^a   García, Concepción ^a   Kurz, Alexander ^b   Rodríguez Navarro, José A ^c   Gispert Sánchez, Suzana ^b   Mena, María A ^c   Auburger, Georg ^b   De Yébenes, Justo García ^d   Fernández Ruiz, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^c Departamento de Neurobiología   (Germany)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Basal ganglia; Cannabinoid signaling system; Parkin; Parkinsonism; PINK1; synuclein

Indexed keywords

ALPHA SYNUCLEIN; CANNABINOID 1 RECEPTOR; MESSENGER RNA; PARKIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; GENE; GENE DELETION; GLOBUS PALLIDUS; MALE; MOUSE; MOUSE MUTANT; NERVE CELL NECROSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARK 6 GENE; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SUBSTANTIA NIGRA; AGE; ANIMAL; AUTORADIOGRAPHY; C57BL MOUSE; CLASSIFICATION; DOWN REGULATION; GENETICS; METABOLISM; METHODOLOGY; PROTEIN BINDING; UPREGULATION;

AGE FACTORS; ALPHA-SYNUCLEIN; ANIMALS; AUTORADIOGRAPHY; BASAL GANGLIA; DOWN-REGULATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN BINDING; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION;

EID: 75349085227     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-92660-4_22     Document Type: Article

References (26)

1. Berrendero F, Romero J, Garćia-Gil L, Suárez I, De la Cruz P, Ramos JA, Fernández-Ruiz J (1998) Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. Biochim Biophys Acta 1407:205-214
2. Brotchie JM (2003) CB1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 3:54-61
3. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22:8797-8807
4. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14:1432-1438
5. Fernández-Espejo E, Caraballo I, Rodríguez de Fonseca F, El Banoua F, Ferrer B, Flores JA, Galán-Rodríguez B (2005) Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 18:591-601
6. García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134:162-170
7. García-Arencibia M, Ferraro L, Tanganelli S, Fernández-Ruiz J (2008) Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neurosci Lett 438:10-13
8. Gerdeman GL, Fernández-Ruiz J (2008) The endocannabinoid system in the physiology and pathophysiology of the basal ganglia. In: Kofalvi A (ed) Cannabinoids and the brain. Springer, Berlin, pp 423-483
9. González S, Mena MA, Lastres-Becker I, Serrano A, de Yébenes JG, Ramos JA, Fernández-Ruiz J (2005) Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. Brain Res 1046:195-206
10. González S, Scorticati C, García-Arencibia M, de Miguel R, Ramos JA, Fernández-Ruiz J (2006) Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res 1073-1074:209-219
11. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agrò A, Maccarrone M (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22:6900-6907
12. Herkenham M, Lynn AB, Little MD, Melvin LS, Johnson MR, de Costa DR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583
13. Itier JM, Ibañez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, Ret G, Joubert C, Periquet M, Araujo F, Negroni J, Casarejos MJ, Canals S, Solano R, Serrano A, Gallego E, Sanchez M, Denefle P, Benavides J, Tremp G, Rooney TA, Brice A, García de Yébenes J (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12:2277-2291
14. Lastres-Becker I, Cebeira M, de Ceballos M, Zeng B-Y, Jenner P, Ramos JA, Fernández-Ruiz J (2001) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 14:1827-1832
15. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19:96-107
16. Lehmann A, Gautier M (1974) Stereotaxic atlas of the brain of the mouse. Centre National de la Recherche Scientifique, Paris Book/1-68
17. Mailleux P, Vanderhaeghen JJ (1993) Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61:1705-1712
18. Pazos MR, Sagredo O, Fernández-Ruiz J (2008) The endocannabinoid system in Huntington's disease. Curr Pharm Des 23:2317-2325
19. Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agro A, Bernardi G, Brusa L, Pierantozzi M, Stanzione P, Maccarrone M (2005) High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol 57:777-779
20. Rodríguez-Navarro JA, Casarejos MJ, Menéndez J, Solano RM, Rodal I, Gómez A, Yébenes JG, Mena MA (2007) Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J Neurochem 103:98-114
21. Romero J, Berrendero F, Garcia-Gil L, de la Cruz P, Ramos JA, Fernández-Ruiz J (1998) Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio) -triphosphate binding in the basal ganglia of aged rats. Neuroscience 84:1075-1083
22. Romero J, Berrendero F, Pérez-Rosado A, Manzanares J, Rojo A, Fernández-Ruiz J, de Yébenes JG, Ramos JA (2000) Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci 66:485-494
23. Rubino T, Massi P, Patrini G, Venier I, Giagnoni G, Parolaro P (1994) Chronic CP-55, 940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study. Neuroreport 5:2493-2496
24. Sagredo O, García-Arencibia M, de Lago E, Finetti S, Decio A, Fernández-Ruiz J (2007) Cannabinoids and neuroprotection in basal ganglia disorders. Mol Neurobiol 36:82-91
25. Sañudo-Peña MC, Tsou K, Walker JM (1999) Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65:703-713
26. Zhao P, Ignacio S, Beattie EC, Abood ME (2008) Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur J Neurosci 27:572-579